Xylocaine

Research use only, not for human use.

Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines.

Lidocaine, an amide local anesthetic, has anti-inflammatory properties in vitro and in vivo, possibly due to an attenuation of pro-inflammatory cytokines, intracellular adhesion molecule-1 (ICAM-1), and reduction of neutrophils influx.(In Vitro):Lidocaine (Lignocaine) (10 nM; 48 hours) decreases significantly cell proliferation.Lidocaine (1-10 nM; 24-72 hours) inhibits cell viability and achieves the most suppressing effects at the concentration of 10 nM and treatment time 48 hours.Lidocaine (10 nM; 48 hours) increases significantly the apoptotic cell rate.Lidocaine (10 nM; 48 hours) down-regulates Cyclin D1 and up-regulates p21 expression significantly.(In Vivo):Lidocaine (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by lidocaine has slower onset and faster recovery compared with thermal nociception block.

——

Lidocaine GMP (Lignocaine) causes completely reversible tail nerve block in rats. Mechanical nociception block produced by Lidocaine GMP has slower onset and faster recovery compared with thermal nociception block.

NSC 40030

GPCR/G Protein

Histamine Receptor

H1 receptor

Cardiovascular Disease

——

137-58-6

234.34

C14H22N2O

>98% (HPLC)

Ethanol: 47 mg/mL (200.56 mM); Water: 9 mg/mL (38.4 mM); DMSO: 47 mg/mL (200.56 mM)

O=C(NC1=C(C)C=CC=C1C)CN(CC)CC

2',6'-Acetoxylidide, 2-(diethylamino)-

(-20℃)

With Ice Pack

≥ 2 years